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Abstract 
Background: Bile acids have been proposed as key mediators of the metabolic effects after 
bariatric surgery. Currently no reports on bile acid profiles after duodenal switch exist, and long-
term data after gastric bypass are lacking.   
 
Objective: To investigate bile acid profiles up to 5 years after Roux-en-Y gastric bypass and 
biliopancreatic diversion with duodenal switch, and to explore the relationship between bile 
acids and weight loss, lipid profile and glucose metabolism.  
 
Settings: Two Scandinavian University Hospitals.  
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Methods: We present data from a randomized, clinical trial of 60 patients with body mass index 
50–60 kg/m2 operated with gastric bypass or duodenal switch. Repeated measurements of total 
and individual bile acids from fasting serum during 5 years after surgery were performed. 
 
Results: Mean concentrations of total bile acids increased from 2.3 µmol/L (95% CI, -0.1 to 4.7) 
at baseline to 5.9 µmol/L (3.5 to 8.3) 5 years after gastric bypass and from 1.0 µmol/L (95% CI, -
1.4 to 3.5) to 9.5 µmol/L (95% CI, 7.1 to 11.9) after duodenal switch, mean between-group 
difference was -4.8 µmol/L (95% CI, -9.3 to -0.3), P=.036. Mean concentrations of primary bile 
acids increased more after duodenal switch, while secondary bile acids increased proportionally 
across the groups. Higher levels of total bile acids at 5 years were associated with lower body 
mass index, greater weight loss and lower total cholesterol.  
 
Conclusions: Total bile acid concentrations increased substantially over 5 years after both 
gastric bypass and duodenal switch, with greater increases in total and primary bile acids after 
duodenal switch.   
 
Keywords: Bariatric surgery; metabolic surgery; Roux-en-Y gastric bypass; gastric bypass, 
biliopancreatic diversion with duodenal switch; duodenal switch; randomized controlled trial; 
randomized clinical trial; bile acids, bile acid profiles 
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Introduction 
Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD/DS) 
provide considerable and durable weight loss and improve obesity-related diseases such as type 
2 diabetes [1,2]. BPD/DS is more effective than RYGB to induce weight loss, improve glycemic 
control and lipid profiles [3-5]. The mechanisms of action for weight loss and metabolic 
improvements are complex and remain largely unknown.  
 
Bile acids (BAs) participate in the control of glucose and lipid metabolism and energy 
homeostasis [6-8]. They act as signaling hormones by activating nuclear receptors and 
membrane coupled receptors in the intestine, liver, muscle and adipose tissue.  Furthermore, 
they regulate the balance of different species of the microbiome, and the microbiome interacts 
reciprocally with the metabolism and composition of BAs [8,9]. BAs have been suggested as 
important mediators of weight loss and metabolic changes after bariatric surgery [10-13], and 
different fractions of BAs have been linked to different features of glucose metabolism [14,15]. 
Most studies report increased BA concentrations after RYGB [16,17], but studies exploring 
changes in BA fractions are inconsistent [18-20].  There are, to our knowledge, no reports of 
changes in BA profiles after BPD/DS, and there are no reports on BA profiles long term after 
bariatric surgery. 
 
We used data from a randomized clinical trial to explore the effects of RYGB and BPD/DS on BA 
concentrations. We aimed to investigate the long term effect of the two procedures on total BA 
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concentrations and fractions, and to explore the relationship between BAs and measures of 
weight loss, blood lipids and glucose metabolism.  
 
Methods 
Study design 
The rationale and design of our randomized clinical trial conducted at two Scandinavian 
University Hospitals has been reported previously [21].  Shortly, patients aged 20-50 years with 
body mass index (BMI, calculated as weight divided by height in meters squared) of 50-60 
seeking bariatric surgery were randomized to receive RYGB or BPD/DS. The regional ethics 
committees approved the protocol, and all patients provided written consent. The trial was 
registered at clinicaltrials.gov Identifier NCT00327912. 
 
The procedures were performed laparoscopically with standardized methodology [21]. In RYGB 
the alimentary limb was 150 cm and the biliopancreatic limb was 50 cm. In BPD/DS, the 
alimentary limb was 200 cm and the common channel was 100 cm. All patients with the 
gallbladder in situ were recommended daily oral intake of ursodeoxycholic acid (500 mg) for 6 
months postoperatively as gall stone prophylaxis. 
 
Results on weight loss, cardio-metabolic risk factors, nutritional status, adverse events, and 
patient-reported outcome measures have been reported previously [5,21-24]. The present 
report implements data from baseline, 1, 2 and 5 years. 
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Blood sample collection, laboratory analysis and calculations 
Venous blood samples were obtained after an overnight fast at each study visit. Samples clotted 
30 minutes at room temperature and serum was separated with centrifugation (1700 x g, 10 
min) and aliquots were stored at -70°C in a biobank for later analyses.  
 
Serum BA profile were analyzed with high performance liquid chromatography (JascoTM, USA) 
coupled to tandem mass spectrometry (Applied Biosystems, Cheshire, UK), in the Department of 
Clinical Biochemistry at the King’s College Hospital NHS Foundation Trust in London, using 
established modifications of a previously described method [25].  The BAs quantified included 
15 fractions. For individual BAs with values below the lowest area of detection we used a 
computer based method with imputation of a random value between 0 and the lowest area of 
detection. Composite concentrations of BAs were calculated by summing concentrations of 
individual BAs.  
 
Statistics 
The sample size was calculated for the primary end point of the study which was change in BMI 
between groups [21]. Because of the explorative nature of this substudy no power calculations 
were performed for the measures in this study. We used linear mixed model analyses to 
estimate mean changes in total and composite values of BA concentrations over time. The linear 
mixed models included fixed effects for procedure, time, and procedure x time interaction. Time 
was modelled as piecewise linear with two knots (1 and 2 years after surgery). A random 
intercept was used. Since cholecystectomy may influence BA concentrations and more patients 
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with BPD/DS had cholecystectomy, we performed sensitivity analyses on total BAs with samples 
obtained after cholecystectomy excluded. We also compared the composition of individual BAs 
and composite values between patients with and without cholecystectomy, and revealed a 
comparable pattern between the groups. Hence we decided to include all patients in the 
descriptive analyses. 
 
For between group changes of individual BAs, we used linear regression with BA concentrations 
at 5 years as dependent variable and the baseline measurement and surgical procedure as 
independent variables. Although the distribution of the BA concentrations was slightly skewed, 
we found the difference in means to be a suitable effect measure, and that the distribution of 
the residuals from the linear regression models did not deviate much from the normal 
distribution.  
 
To explore the relationship between total BA concentrations and measures of weight loss, lipid 
and glucose metabolism we used Spearman’s rank order coefficient. A two-tailed P <.05 was 
considered statistically significant. Data were analyzed with Stata 14 College Station, TX 
(StataCorp LP) and IBM SPSS Statistics for Windows, version 24, Armonk, NY (IBM Corporation).  
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Results 
Patient characteristics are described in Table 1. Before surgery, 18% of the patients had type 2 
diabetes, and all of these patients experienced partial or complete remission 5 years after 
surgery. At 1, 2 and 5 years, 1 (1.7%), 2 (3.3%) and 5 (8.3%) of the patients were lost to follow-
up, respectively. Five patients (3 RYGB and 2 BPD/DS) had cholecystectomy before study 
inclusion.  Additional 6 patients (1 RYGB and 5 BPD/DS) had cholecystectomy during the study.  
As previously reported, patients with BPD/DS had substantially greater BMI and weight loss 
compared to RYGB patients, corresponding to a difference of 24.9 kg or 8.5 kg/m2 between 
groups[5].   
 
Total and composite values of BAs are presented in Table 2 and show that total bile acid 
concentrations increased significantly more after BPD/DS compared to RYGB.  We observed 
large intra- and inter-variability of total BAs after both procedures, and the variability tended to 
increase after surgery (Figure 1).  
 
At 5 years, patients with cholecystectomy had higher concentrations of total BAs than patients 
without cholecystectomy; mean 19.7 µmol/L (10.6 to 28.8) vs  4.6 µmol/L (95% CI, 3.2 to 5.9), 
P<.001 (Figure 1). We therefore did sensitivity analysis with only patients with the gall bladder in 
situ included (Table 2).  
 
The concentrations of individual BAs are shown in Table 3. The larger increase in total BA 
concentrations after BPD/DS compared to RYGB was primarily driven by greater increases in 
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primary BAs, predominantly  the unconjugated primary BAs cholic and chenodeoxycholic acid 
and their  glycine-conjugates  (Table 2 and 3). The concentrations of secondary BAs increased 
after surgery in both groups, with no between-group difference. The composition of BAs 
changed differently, with an increase in the proportion of primary BAs after BPD/DS and an 
increase in the proportion of secondary BAs after RYGB (Table 1). 
 
The ratio of the 12α-hydroxylated / non-12α-hydroxylated BAs increased from 0.8 (95% CI, 0.6 
to 1.0) at baseline to 1.1 (95% CI, 0.9 to 1.3) 5 years after RYGB (P=.04) and from 0.7 (95% CI, 0.6 
to 0.9) to 1.3 (1.0 to 1.5) after BPD/DS (P<.001). Mean between group difference was 0.2 (95% 
CI, -0.1 to 0.5); P=.21.  
   
At 5 years, higher levels of fasting total BA concentrations were associated with lower BMI and 
measures of weight loss (Table 4). We also observed an inverse correlation between total BAs 
and total cholesterol. Changes in total levels of BA concentrations between baseline and 5 years 
correlated significantly with weight loss. 
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Discussion 
In this study of BA profiles during 5 years of RYGB and BPD/DS, we observed substantial increase 
in the fasting serum concentrations after both procedures, with greater increase in total BA 
concentrations after BPD/DS compared to RYGB. The composition of BAs changed differently 
across the groups.  
 
Several other studies have investigated BA concentrations after RYGB. Most short-term studies 
(< 2 months after surgery) report unchanged or decreased levels of total BAs [26-28], while 
most studies reporting data from several months and years after surgery report increased  
concentrations [18,20,29-32]. Our findings are in accordance with the existent literature, and 
extend the current knowledge by showing that the BA levels apparently continue to increase up 
to 5 years after RYGB. Changes in BAs after BPD/DS have not previously been explored. 
Interestingly, in a model of duodenal-jejunal bypass with short and long biliopancreatic limbs, 
increased BA concentrations were observed in rats with long biliopancreatic limb, together with 
suppression of weight gain and improved glucose metabolism [33]. This experimental study 
supports that a long biliopancreatic limb may be important for the metabolic improvements 
after bariatric surgery and suggests that BAs play a role, but the causal relationship between 
BAs and the metabolic improvements is still uncertain. 
 
The mechanisms for the higher BA concentrations after BPD/DS compared to RYGB are 
unknown, and can arise through several mechanisms. Differences in intestinal absorption may 
contribute. The longer biliopancreatic limb in BPD/DS leads to transportation of high 
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concentrations of primary BAs through a longer segment of the small bowel before they mix 
with food and promote fat digestion and absorption in the common channel, and could 
therefore be more available for absorption. We found that the higher concentrations of primary 
BAs after BPD/DS were predominantly due to increases in the unconjugated and glycine-
conjugated primary BAs. In normal anatomy, BAs in the upper intestine are dominated  by 
primary conjugated BAs [34]. One possible explanation for the rise in unconjugated BAs could 
be that microbial contamination of the small intestine due to altered gut anatomy causes 
bacterial deconjugation of BAs and subsequently absorption in the biliopancreatic limb [34-36]. 
This could mean that the great elevation of BAs that we observe after BPD/DS (and also RYGB) 
not necessarily reflects an actual increase in the size of the bile salt pool, but could rather be a 
result of shorter enterohepatic cycling. 
 
The repeated measurements in our study revealed that BAs continued to increase years after 
surgery. Changed microbial metabolism may be involved as they can modulate the BA pool [37]. 
Changes in BA synthesis or excretion could also be involved [38]. Cholesterol is an essential 
constituent of BAs. Our finding of an inverse correlation between total BAs and total cholesterol, 
together with a greater reduction in total cholesterol, LDL cholesterol and triglycerides after 
BPD/DS compared to RYGB in the main study, leads us to speculate that increased hepatic 
production and/or increased fecal excretion of BAs contribute to our observations.  
 
We found significantly higher serum BA levels in patients with cholecystectomy compared to 
patients with the gall bladder in situ 5 years after surgery. This may, completely or partly, be 
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attributable to increased cycling of the BA pool in the enterohepatic circulation due to lack of 
storage capacity [39,40]. 
 
We observed a relationship between higher total BA concentrations at 5 years and lower BMI, 
greater weight loss and lower serum total cholesterol. These observations must be considered 
as explorative and no conclusions about a causal relationship between these variables and bile 
acid concentrations can be done. As in several other studies, we were not able to demonstrate 
any correlation between BAs and markers of glucose metabolism and insulin resistance 
[18,20,27,28].  We found large variations in fasting BA concentrations both within and between 
individuals, as depicted in Figure 1. This is in line with studies of non-bariatric subjects, which 
found large diurnal variations within individuals [41,42] and large variations in production and 
concentrations between individuals [43,44].  
 
Insulin regulates BA composition, in part by regulating the BA 12-α hydroxylase (CYP8B1), and it 
has been shown that a high ratio of 12α-hydroxylated / non-12α-hydroxylated BAs is associated 
with more insulin resistance [14].  A study of patients with type 2 diabetes observed, contrary to 
their hypothesis, an increase in this ratio after RYGB [28]. Our study, which mostly included non-
diabetic subjects, also demonstrated an increased ratio after both procedures at 5 years.    
 
Strengths of this study include the randomized design with a well-defined patient population, 
close to complete follow-up up at all time points, and standardized surgical procedures. BA 
composition was carefully characterized at several time points and includes long-term 
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evaluation. Limitations include measurements of BAs in peripheral blood. We did not measure 
post-prandial BA responses, markers of production, fecal excretion, enteric hormones or fecal 
microbiome, which would have helped us to better understand the physiological changes that 
underlie our findings. The findings of this study may not generalize to patients outside the BMI 
and age restriction in our study, and probably of more importance, to patients with type 2 
diabetes or severe metabolic disease. Previous studies have shown different bile acid profiles 
and responses in subjects with type 2 diabetes compared to non-diabetic subjects both before 
and after bariatric surgery [11,45]. 
 
We have demonstrated larger increases in serum BAs and a different change in bile acid species 
and composition after BPD/DS than after RYGB. Whether there is a causal relationship between 
the higher increase in BAs after BPD/DS and the superior metabolic effects compared to RYGB 
remains unknown. Our findings of a relationship between BAs and measures of weight and 
weight loss and total cholesterol may suggest that BAs play a role in the metabolic 
improvements after the two procedures, but a causal relationship is still unknown. Other 
mechanisms are involved, and isolating the effect of changes in the enterohepatic circulations of 
BAs has not been achieved. Further mechanistic studies are warranted to reveal the physiology 
of altered BA concentrations after bariatric surgery, and to investigate the possible impact of 
BAs on the metabolic improvements. Measures from patients with normal gut anatomy have 
shown large variability in the BA concentrations within and between individuals, and our study 
implicates that this variability fluctuates even more after RYGB and BPD/DS.  This, and the fact 
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that cholecystectomy may result in a substantial change in the enterohepatic circulation, should 
be taken into account in the planning of future studies.   
 
Conclusions 
Fasting serum concentrations of total BAs increased substantially over 5 years after both RYGB 
and BPD/DS. Patients undergoing BPD/DS had greater increase in total and primary BAs in 
comparison to RYGB. At 5 years, there was a positive correlation between total BA 
concentration and weight loss, and an inverse correlation between total BA concentrations and 
BMI and total cholesterol.  
 
Acknowledgement 
We thank the Norwegian Society for Gastroenterology for a research grant for this project. 
 
References 
 [1] Puzziferri N, Roshek TB, 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a 
systematic review. Jama. 2014;312:934-42. 
 [2] Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional 
medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, 
single-centre, randomised controlled trial. Lancet. 2015;386:964-73. 
 [3] Hedberg J, Sundstrom J, Sundbom M. Duodenal switch versus Roux-en-Y gastric bypass for 
morbid obesity: systematic review and meta-analysis of weight results, diabetes resolution and 
early complications in single-centre comparisons. Obes Rev. 2014;15:555-63. 
 [4] Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: 
systematic review and meta-analysis. Am J Med. 2009;122:248-56. 
 [5] Risstad H, Sovik TT, Engstrom M, et al. Five-year outcomes after laparoscopic gastric bypass and 
laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical 
trial. JAMA Surg. 2015;150:352-61. 
 [6] Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014;86:62-8. 
 [7] Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia 
and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006-11. 
18 
 
 [8] Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting 
intracellular thyroid hormone activation. Nature. 2006;439:484-9. 
 [9] Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J 
Lipid Res. 2006;47:241-59. 
 [10] Kohli R, Seeley RJ. Diabetes: the search for mechanisms underlying bariatric surgery. Nat Rev 
Endocrinol. 2013;9:572-4. 
 [11] Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in 
diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859-64. 
 [12] Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical 
sleeve gastrectomy. Nature. 2014;509:183-8. 
 [13] Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight 
after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2:152-64. 
 [14] Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with 
increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013;62:4184-91. 
 [15] Wewalka M, Patti ME, Barbato C, et al. Fasting serum taurine-conjugated bile acids are elevated 
in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab. 
2014;99:1442-51. 
 [16] Cole AJ, Teigen LM, Jahansouz C, et al. The Influence of Bariatric Surgery on Serum Bile Acids in 
Humans and Potential Metabolic and Hormonal Implications: a Systematic Review. Curr Obes 
Rep. 2015;4:441-50. 
 [17] Fouladi F, Mitchell JE, Wonderlich JA, et al. The Contributing Role of Bile Acids to Metabolic 
Improvements After Obesity and Metabolic Surgery. Obes Surg. 2016;26:2492-502. 
 [18] Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not 
laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 
2013;98:E708-12. 
 [19] Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12alpha-
hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond). 
2015;39:806-13. 
 [20] Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates 
of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg. 2012;22:1473-80. 
 [21] Sovik TT, Taha O, Aasheim ET, et al. Randomized clinical trial of laparoscopic gastric bypass 
versus laparoscopic duodenal switch for superobesity. Br J Surg. 2010;97:160-6. 
 [22] Sovik TT, Aasheim ET, Taha O, et al. Weight loss, cardiovascular risk factors, and quality of life 
after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med. 2011;155:281-91. 
 [23] Aasheim ET, Bjorkman S, Sovik TT, et al. Vitamin status after bariatric surgery: a randomized 
study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90:15-22. 
 [24] Sovik TT, Karlsson J, Aasheim ET, et al. Gastrointestinal function and eating behavior after gastric 
bypass and duodenal switch. Surg Obes Relat Dis. 2012. 
 [25] Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human plasma by 
liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step 
method. Clin Chem Lab Med. 2003;41:1633-41. 
 [26] Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: a 
1-year prospective randomized pilot trial. Obesity (Silver Spring). 2013;21:E660-8. 
 [27] Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric 
bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. 
Am J Physiol Endocrinol Metab. 2012;303:E122-31. 
 [28] Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12alpha-
hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond). 2015. 
19 
 
 [29] Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric 
bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 
2009;17:1671-7. 
 [30] Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid 
responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013;48:1257-64. 
 [31] Jorgensen NB, Dirksen C, Bojsen-Moller KN, et al. Improvements in glucose metabolism early 
after gastric bypass surgery are not explained by increases in total bile acids and fibroblast 
growth factor 19 concentrations. J Clin Endocrinol Metab. 2015;100:E396-406. 
 [32] Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in 
promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613-9. 
 [33] Miyachi T, Nagao M, Shibata C, et al. Biliopancreatic limb plays an important role in metabolic 
improvement after duodenal-jejunal bypass in a rat model of diabetes. Surgery. 2016;159:1360-
71. 
 [34] Dietschy JM. Mechanisms for the intestinal absorption of bile acids. J Lipid Res. 1968;9:297-309. 
 [35] Picard M, Frederic Simon H, Stefane L, et al. Complications of combined gastric restrictive and 
malabsorptive procedures: part 2. Curr Surg. 2003;60:274-9; discussion 79-81. 
 [36] Tabaqchali S, Hatzioannou J, Booth CC. Bile-salt deconjugation and steatorrhoea in patients with 
the stagnant-loop syndrome. Lancet. 1968;2:12-6. 
 [37] Ridlon JM, Kang DJ, Hylemon PB, et al. Bile acids and the gut microbiome. Curr Opin 
Gastroenterol. 2014;30:332-8. 
 [38] Ferrannini E, Camastra S, Astiarraga B, et al. Increased Bile Acid Synthesis and Deconjugation 
After Biliopancreatic Diversion. Diabetes. 2015;64:3377-85. 
 [39] Shaffer EA, Small DM. Biliary lipid secretion in cholesterol gallstone disease. The effect of 
cholecystectomy and obesity. J Clin Invest. 1977;59:828-40. 
 [40] Escalona A, Munoz R, Irribarra V, et al. Bile acids synthesis decreases after laparoscopic sleeve 
gastrectomy. Surg Obes Relat Dis. 2016;12:763-9. 
 [41] Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and 
associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One. 
2011;6:e25006. 
 [42] Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is 
asynchronous with cholesterol synthesis. Gastroenterology. 2005;129:1445-53. 
 [43] Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related 
to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern 
Med. 2011;270:580-8. 
 [44] Xie G, Wang Y, Wang X, et al. Profiling of Serum Bile Acids in a Healthy Chinese Population Using 
UPLC-MS/MS. J Proteome Res. 2015;14:850-9. 
 [45] Vincent RP, Omar S, Ghozlan S, et al. Higher circulating bile acid concentrations in obese patients 
with type 2 diabetes. Ann Clin Biochem. 2013;50:360-4. 
 
 
 
 
 
20 
 
 
 
Table 1. Baseline and 5-year data by treatment group 
Variable RYGB (n=31) BPD/DS (n=29) 
Age at inclusion, years 35.2 (7.0) 36.1 (5.3) 
Female, n (%) 23 (74.2) 19 (65.5) 
White, n (%) 30 (96.8) 27 (93.1) 
Body weight, kg   
  Baseline 162.1 (24.1) 162.2 (19.7) 
  5 y change from baseline  -42.8 (21.6) -66.5 (23.3) 
BMI (kg/m
2
)   
  Baseline 54.8 (3.2) 55.2 (3.5) 
  5 y change from baseline  -13.1 (7.3) -20.4 (7.1) 
Total cholesterol, mg/dL   
  Baseline 186 (34) 186 (26) 
  5 y change from baseline  -7 (29) -53 (23) 
LDL-C, mg/dL   
  Baseline 110 (25) 110 (24) 
  5 y change from baseline  -10 (25) -40 (24) 
HDL-C, mg/dL   
  Baseline 46 (10) 45 (10) 
  5 y change from baseline  17 (12) 7 (10) 
Triglycerides, mg/dL   
  Baseline 147 (75) 160 (59) 
  5 y change from baseline  -62 (61) -86 (51) 
Glucose, mg/dL   
  Baseline 110 (31) 114 (38) 
  5 y change from baseline  -10 (28) -27 (42) 
Cholecystectomy, n (%)   
  Baseline 3 (9.7) 2 (6.9) 
  5 y 4 (12.9) 7 (24.1) 
Type 2 diabetes, n (%)
   
  Baseline 5 (16.1) 6 (20.7) 
  5 y 0 0 
Use of glucose-lowering medication, n (%) 
 
 
  Baseline 3 (9.7)
 
2 (6.9) 
  5 y 0 0 
Hypertension, n (%)   
  Baseline 8 (25.8) 8 (27.6) 
  5 y 4 (14.8) 7 (25.0) 
Metabolic syndrome, n (%)   
  Baseline 20 (64.5) 23 (79.3) 
  5 y 3 (11.1) 1 (3.6) 
21 
 
Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with 
duodenal switch; y, years; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol.  
Mean (SD) are reported for continuous variables.  
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Table 2. Composite measures of bile acid concentrations after RYGB and BPD/DS up to 5 years after 
surgery 
Bile acids  Mean 
concentrations 
(95% CI)  
Mean change (5y–
B) within group 
(95% CI);  
P value 
Mean change between 
groups (5y–B);  
P value 
Total, µmol/L     
  Preop RYGB 2.3 (-0.1, 4.7) 3.6 (0.5, 6.8); P=.025 -4.8 (-9.3, -0.3); 
P=.036 
 BPD/DS 1.0 (-1.4, 3.5) 8.5 (5.3, 11.6); 
P<.001 
 
  1 y RYGB 2.5 (0.1, 5.0   
 BPD/DS 6.4 (3.9, 9.0)   
  2 y RYGB 4.7 (2.3, 7.1)   
 BPD/DS 8.2 (5.6, 10.8)   
  5 y RYGB 5.9 (3.5, 8.3)   
 BPD/DS 9.5 (7.1, 11.9)   
Glycine 
conjugated, 
µmol/L  
    
  Preop RYGB 1.2 (-0.3, 2.7) 1.7 (-0.2, 3.7); P=.08 -2.4 (-5.2, 0.3); P=.09 
 BPD/DS 0.6 (-1.0, 2.1) 4.2 (2.2, 6.1); P<.001  
  1 y RYGB 1.2 (-0.3, 2.8)   
 BPD/DS 2.8 (1.2, 4.4)   
  2 y RYGB 1.7 (0.2, 3.1)   
 BPD/DS 3.5 (1.9, 5.1)   
  5 y RYGB 3.0 (1.5, 4.5)   
 BPD/DS 4.7 (3.3, 6.2)   
Taurine 
conjugated, 
µmol/L 
    
  Preop RYGB 0.14 (0.02, 
0.27) 
0.2 (0.009, 0.3); 
P=.37 
0.1 (-0.1, 0.3); P=.50 
 BPD/DS 0.001 (-0.12, 
0.13) 
0.1 (-0.1, 0.2); P=.26  
  1 y RYGB 0.1 (-0.008, 
0.2) 
  
 BPD/DS 0.1 (-0.02, 0.2)   
  2 y RYGB 0.1 (-0.004, 
0.2) 
  
 BPD/DS 0.1 (-0.01, 0.3)   
  5 y RYGB 0.2 (0.009, 0.3)   
 BPD/DS 0.1 (-0.1, 0.2)   
Total 
unconjugated, 
µmol/L 
    
  Preop RYGB 0.9 (-0.6, 2.5) 1.7 (-0.3, 3.7); P=.09 -2.5 (-5.3, 0.3); P=.09 
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 BPD/DS 0.5 (-1.1, 2.0) 4.2 (2.2, 6.2); P<.001  
  1 y RYGB 1.2 (-0.4, 2.7)   
 BPD/DS 3.5 (1.9, 5.1)   
  2 y RYGB 2.9 (1.4, 4.4)   
 BPD/DS 4.6 (3.0, 6.3)   
  5 y RYGB 2.7 (1.2, 4.2)   
 BPD/DS 4.7 (3.2, 6.2)   
Proportion 
Conjugated, % 
    
  Preop RYGB 64.8 (54.0, 
75.5) 
-12.9 (-26.9, 1.0); 
P=.07 
6.9 (-12.7, 26.5);P=.49 
 BPD/DS 54.9 (44.0, 
65.8) 
-19.8 (-33.6, -6.0); 
P=.005 
 
  1 y RYGB 54.3 (43.5, 
65.0) 
  
 BPD/DS 47.3 (36.3, 
58.2) 
  
  2 y RYGB 57.5 (47.1, 
67.9) 
  
 BPD/DS 42.2 (31.1, 
53.4) 
  
  5 y RYGB 51.8 (41.3, 
62.3) 
  
 BPD/DS 35.1 (24.9, 
45.3) 
  
Proportion 
unconjugated, % 
    
  Preop RYGB 35.2 (24.5, 
46.0) 
12.9 (-1.0, 26.9); 
P=.07 
-6.9 (-26.5, 12.7); 
P=.49 
 BPD/DS 45.1 (34.2, 
56.0) 
19.8 (6.0, 33.6); 
P=.005 
 
  1 y RYGB 45.7 (35.0, 
56.5) 
  
 BPD/DS 52.7 (41.8, 
63.7) 
  
  2 y RYGB 42.5 (32.1, 
52.9) 
  
 BPD/DS 57.8 (46.6, 
68.9) 
  
  5 y RYGB 48.2 (37.7, 
58.7) 
  
 BPD/DS 64.9 (54.7, 
75.1) 
  
Primary, µmol/L     
  Preop RYGB 1.6 (-0.3, 3.4) 2.4 (-0.1, 4.8); P=.06 -4.3 (-7.8, -0.9); 
P=.015 
 BPD/DS 0.7 (-1.2, 2.6) 6.7 (4.2, 9.1); P<.001  
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  1 y RYGB 1.7 (-0.2, 3.6)   
 BPD/DS 4.9 (3.0, 6.9)   
  2 y RYGB 3.4 (1.6, 5.2)   
 BPD/DS 5.8 (3.8, 7.8)   
  5 y RYGB 4.0 (2.1, 5.8)   
 BPD/DS 7.4 (5.6, 9.2)   
Secondary, 
µmol/L 
    
  Preop RYGB 0.7 (-0.03, 1.4) 1.3 (0.3, 2.2); P=.01 -0.5 (-1.9, 0.9); P=.47 
 BPD/DS 0.4 (-0.4, 1.1) 1.8 (0.8, 2.7); P<.001  
  1 y RYGB 0.8 (0.1, 1.6)   
 BPD/DS 1.5 (0.7, 2.3)   
  2 y RYGB 1.3 (0.5, 2.0)   
 BPD/DS 2.4 (1.6, 3.2)   
  5 y RYGB 2.0 (1.2, 2.7)   
 BPD/DS 2.1 (1.4, 2.9)   
Proportion  
Primary, % 
    
  Preop RYGB 69.0 (61.7, 
76.3) 
-12.2 (-21.7, -2.6); 
P=.012 
-28.4 (-41.8, -15.0); 
P<.001 
 BPD/DS 56.9 (49.5, 
64.3) 
16.3 (6.9, 25.7); 
P<.001 
 
  1 y RYGB 62.5 (55.2, 
69.8) 
  
 BPD/DS 69.3 (61.8, 
76.8) 
  
  2 y RYGB 64.6 (57.5, 
71.7) 
  
 BPD/DS 75.2 (67.6, 
82.8) 
  
  5 y RYGB 56.9 (50.0, 
64.0) 
  
 BPD/DS 73.2 (66.2, 
80.1) 
  
Proportion  
secondary, % 
    
  Preop RYGB 31.0 (23.7, 
38.3) 
12.2 (2.6, 21.7); 
P=.012 
28.4 (15.0, 41.8); 
P<.001 
 BPD/DS 43.1 (35.7, 
50.4) 
-16.3 (-25.7, -6.9); 
P<.001 
 
  1 y RYGB 37.5 (30.2, 
44.8) 
  
 BPD/DS 30.7 (23.2, 
38.2) 
  
  2 y RYGB 35.4 (28.3, 
42.5) 
  
 BPD/DS 24.8 (17.2,   
25 
 
32.4) 
  5 y RYGB 43.1 (36.0, 
50.3) 
  
 BPD/DS 26.8 (19.9, 
33.8) 
  
Total,  
cholecystectomy 
excluded
a 
    
  Preop RYGB 2.1 (0.3, 3.9) 1.4 (-1.0, 3.7); P=.26 -3.4 (-6.8, -0.4); 
P=.048 
 BPD/DS 1.1 (-0.8, 2.9) 4.8 (2.4, 7.2); P<.001  
  1 y RYGB 2.5 (0.7, 4.3)   
 BPD/DS 6.1 (4.2, 8.0)   
  2 y RYGB 3.7 (1.9, 5.5)   
 BPD/DS 6.5 (4.6, 8.5)   
  5 y RYGB 3.5 (1.6, 5.3)   
 BPD/DS 5.9 (4.0, 7.8)   
Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with 
duodenal switch; Preop, preoperatively.  
a
Sensitivity analyses with bile acid concentration measures obtained after patients with 
cholecystectomy (n=11) excluded. 
 
 
Table 3. Individual bile acid concentrations and fractions before and 5 years after RYGB and BPD/DS 
 Procedure Preop  5 y  Mean 
between-
group 
change
a 
P 
value
a 
Primary 
unconjugated 
bile acids 
     
CA      
µmol/L, mean 
(95% CI) 
RYGB 0.22 (0.07, 
0.39) 
0.70 (-
0.13, 
1.53) 
0.84 (-0.36, 
2.04) 
.16 
 BPD/DS 0.06 (0.03, 
0.09) 
1.63 
(0.82, 
2.46) 
  
  % TBA, mean 
(95% CI) 
RYGB 7.1 (3.7, 
10.4) 
8.0 (4.0, 
12.1) 
10.2 (2.9, 
17.4) 
.007 
 BPD/DS 4.0 (2.3, 5.6) 18.7 
(12.8, 
24.6) 
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CDCA      
µmol/L, mean 
(95% CI) 
RYGB 0.26 (0.11, 
0.40) 
1.03 (-
0.19, 
2.25) 
0.18 (-1.17, 
1.52) 
.79 
 BPD/DS 0.12 (0.07, 
0.17) 
1.37 
(0.85, 
1.89) 
  
  % TBA, mean 
(95% CI) 
RYGB 9.1 (5.7, 
12.6) 
10.3 (5.0, 
15.7) 
7.1 (0.4, 
13,9) 
.039 
 BPD/DS 7.9 (5.4, 
10.4) 
17.6 
(13.3, 
21.9) 
  
Primary 
conjugated bile 
acids 
     
GCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.19 (0.11, 
0.28) 
0.32 
(0.17, 
0.47) 
0.91 (-0.02, 
1.83) 
.05 
 
BPD/DS 0.12 (0.08, 
0.16) 
1.26 
(0.36, 
2.16) 
  
  % TBA, mean 
(95% CI) 
RYGB 7.9 (5.7, 
10.1) 
7.6 (5.4, 
9.7) 
0.7 (-3.0, 
4.5) 
.69 
 BPD/DS 7.3 (5.7, 8.9) 8.3 (5.1, 
11.4) 
  
TCA      
  µmol/L, mean 
(95% CI)) 
RYGB 0.04 (0.01, 
0.07) 
0.05 
(0.03, 
0.07) 
0.001 (-
0.03, 0.03) 
.93 
 
BPD/DS 0.03 (0.02, 
0.03) 
0.05 
(0.02, 
0.07) 
  
  % TBA, mean 
(95% CI) 
RYGB 1.4 (0.7, 2.1) 2.2 (1.1, 
3.3) 
-0.02 (-
0.04, 0.01) 
.28 
 BPD/DS 2.0 (1.5, 5.6) 0.8 (0.4, 
1.2) 
  
GCDCA      
  µmol/L, mean 
(95% CI)) 
RYGB 0.65 (0.44, 
0.85) 
1.04 
(0.59, 
1.50) 
1.49 (-0.57, 
3.04) 
.15 
 
BPD/DS 0.39 (0.27, 
0.51) 
2.73 
(0.79, 
4.67) 
  
  % TBA, mean 
(95% CI) 
RYGB 28.2 (24.2, 
32.2) 
24.1 
(18.0, 
30.1) 
-7.4 (-15.8, 
1.0) 
.08 
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 BPD/DS 24.1 (19.7, 
28.5) 
19.3 
(12.3, 
26.2) 
  
TCDC      
  µmol/L, mean 
(95% CI) 
RYGB 0.06 (0.03, 
0.09) 
0.10 
(0.05, 
0.14) 
  
 BPD/DS 0.04 (0.03, 
0.05) 
0.07 
(0.04, 
0.10) 
  
  % TBA, mean 
(95% CI) 
RYGB 3.0 (2.1, 3.9) 2.8 (1.6, 
4.1) 
-1.7 (-3.0, -
0.5) 
.009 
 BPD/DS 2.8 (1.9, 3.7) 1.1 (0.6, 
1.6) 
  
Secondary 
unconjugated 
bile acids 
     
DCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.3 (0.1, 0.4) 0.8 (0.3, 
1.3) 
0.12 (-0.43, 
0.66) 
.67 
 BPD/DS 0.2 (0.2, 0.3) 0.9 (0.6, 
1.2) 
  
  % TBA, mean 
(95% CI) 
RYGB 11.3 (7.8, 
14.8) 
16.0 
(12.5, 
19.4) 
-1.3 (-7.7, 
5.1) 
.68 
 BPD/DS 14.8 (11.5, 
18.1) 
15.5 
(10.0, 
20.9) 
  
UDCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.06 (0.04, 
0.08) 
0.09 
(0.01, 
0.17) 
0.02 (-0.07, 
0.10) 
.74 
 BPD/DS 0.05 (0.03, 
0.06) 
0.10 
(0.06, 
0.14) 
  
  % TBA, mean 
(95% CI) 
RYGB 3.2 (2.3, 4.1) 1.8 (1.2, 
2.3) 
0.3 (-0.7, 
1.3) 
.55 
 BPD/DS 3.1 (2.3, 4.0) 2.1 (1.1, 
3.0) 
  
LCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.07 (0.06, 
0.09) 
0.07 
(0.06, 
0.09) 
0.01 (-0.02, 
0.31) 
.51 
 BPD/DS 0.07 (0.05, 
0.09) 
0.08 
(0.07, 
0.10) 
  
  % TBA, mean RYGB 4.5 (2.9, 6.1) 3.8 (2.0, -1.9 (-4.0, .08 
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(95% CI) 5.6) 0.2) 
 BPD/DS 5.6 (3.6, 7.6) 2.0 (0.8, 
3.2) 
  
Secondary 
conjugated bile 
acids 
     
GDCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.2 (0.1, 0.3) 0.5 (0.3, 
0.6) 
0.34 (-0.38, 
1.05) 
.34 
 BPD/DS 0.1 (0.1, 0.2) 0.8 (0.1, 
1.5) 
  
  % TBA, mean 
(95% CI) 
RYGB 8.5 (6.5, 
10.4) 
11.9 (9.1, 
14.7) 
-5.2 (-8.7, -
1.7) 
.005 
 BPD/DS 8.1 (5.8, 
10.5) 
6.7 (4.5, 
9.0) 
  
TDCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.04 (0.03, 
0.05) 
0.07 
(0.04, 
0.09) 
-0.02 (-
0.05, 0.01) 
.28 
 BPD/DS 0.02 (0.02, 
0.03) 
0.04 
(0.02, 
0.06) 
  
  % TBA, mean 
(95% CI) 
RYGB 2.5 (1.5, 3.5) 2.2 (1.5, 
2.9) 
-1.4 (-2.2, -
0.6) 
.001 
 BPD/DS 1.8 (1.1, 2.4) 0.7 (0.3, 
1.1) 
  
GUDCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.10 (0.07, 
0.14) 
0.09 
(0.03, 
0.15) 
0.09 (-0.04, 
0.2) 
.18 
 BPD/DS 0.07 (0.05, 
0.09) 
0.18 
(0.07, 
0.29) 
  
  % TBA, mean 
(95% CI) 
RYGB 4.9 (3.8, 5.9) 2.2 (1.4, 
3.1) 
-0.1 (-
1.2,0.9) 
.82 
 BPD/DS 4.5 (3.5, 5.6) 2.2 (1.4, 
2.9) 
  
TUDCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.02 (0.01, 
0.02) 
0.02 
(0.02, 
0.02) 
-0.001 (-
0.006, 
0.005) 
.78 
 BPD/DS 0.02 (0.02, 
0.02) 
0.02 
(0.02, 
0.02) 
  
  % TBA, mean 
(95% CI) 
RYGB 1.1 (0.7, 1.5) 1.0 (0.5, 
1.5) 
-0.6 (-1.1, 
0.002) 
.05 
 BPD/DS 1.5 (1.1, 1.8) 0.4 (0.2,   
29 
 
0.7) 
GLCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.06 (0.04, 
0.08) 
0.08 
(0.06, 
0.10) 
  
 BPD/DS 0.09 (0.07, 
0.11) 
0.09 
(0.07, 
0.11) 
  
  % TBA, mean 
(95% CI) 
RYGB 3.3 (1.9, 4.7) 3.4 (1.8, 
4.9) 
-1.2 (-3.4, 
1.0) 
.28 
 BPD/DS 6.7 (5.0, 8.3) 2.2 (0.9, 
3.5) 
  
TLCA      
  µmol/L, mean 
(95% CI) 
RYGB 0.07 (0.05, 
0.10) 
0.06 
(0.04, 
0.08) 
  
 BPD/DS 0.08 (0.06, 
0.10) 
0.09 
(0.07, 
0.11) 
  
  % TBA, mean 
(95% CI) 
RYGB 4.2 (2.4, 6.0) 2.7 (1.5, 
3.8) 
0.1 (-1.8, 
2.0) 
.92 
 BPD/DS 5.9 (3.9, 7.8) 2.5 (1.0, 
4.0) 
  
Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with 
duodenal switch; Preop, preoperatively; TBA, total bile acids; CA, cholic acid; CDCA, 
chenodeoxycholic acid; GCA, glycocholic acid; TCA, taurocholic acid; GCDCA, 
glycochenodeoxycholic acid; TCDC, taurochenodeoxycholic acid; DCA, deoxycholic acid; 
UDCA, ursodeoxycholic acid; LCA, lithocholic acid; GDCA, glycodeoxycholic acid;  TDCA, 
taurodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; TUDCA, tauroursodeoxycholic 
acid; GLCA, glycolithocholic acid; TLCA, taurolithocholic acid. 
a
From multiple regression with the 5 y value as dependent variable and procedure and 
preoperative value as independent variable.  
The lowest area of detection for the individual bile acids: 0.05 µmol/L (TUDCA), 0.06 µmol/L 
(GUDCA), 0.07 µmol/L (CDCA, TCA, TCDCA, UDCA, TDCA), 0.08 µmol/L (DCA), 0.10 
µmol/L (GCA) 0.14 (GDCA), 0.16 µmol/L (GCDCA, LCA), 0.17 µmol/L (GLCA, TLCA). 
Random imputation (between 0 and lowest area of detection) was used for measurements below 
the lowest area of detection.  
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Table 4. Correlation analyses of fasting serum concentrations of total bile acids and BMI, fasting serum 
lipids and measures of glucose metabolism at 5 years  
 Spearman’s Rho
a 
95% CI P value 
5y measurements Total bile acid 
concentrations
 
 
(n=43)
 
  
Body mass index (kg/m
2
) -0.31 -0.56, -0.01 .042 
Body mass index change (5y–B) -0.35 -0.59, -0.06 .023 
Body weight, kg -0.26 -0.52, 0.04 .09 
Body weight change (5y–B), kg -0.39 -0.62, -0.10 .010 
Body weight change (5y–B), % -0.35 -0.56, -0.06 .021 
Total cholesterol, mg/dL -0.33 -0.57, -0.03 .036 
LDL-C, mg/dL -0.28 -0.54, 0.02 .08 
HDL-C, mg/dL -0.09 -0.39, 0.21 .56 
Triglycerides, mg/dL -0.20 -0.47, 0.11 .21 
Glucose, mg/dL -0.17 -0.45, 0.14 .28 
HbA1c, % -0.12 -0.41, 0.19 .46 
C-peptide, ng/mL -0.19 -0.46, 0.12 .24 
Insulin, µIU/mL -0.30 -0.55, 0.00 .05 
Proinsulin / insulin ratio 0.01 -0.38, 0.39 .93 
HOMA-IR -0.29 -0.54, 0.01 .06 
    
Change from baseline to 5y
b 
Change in total bile 
acid  
Concentrations
b
 
(n=39) 
  
Body mass index (kg/m
2
) -0.30 -0.56, 0.02 .06 
Body weight (kg) -0.35 -0.60, -0.04 .041 
Body weight (%) -0.31 -0.57, 0.01 .06 
Total cholesterol, mg/dL -0.29 -0.55, 0.03 .08 
LDL-C,  -0.31 -0.57, 0.01 .06 
HDL-C, mg/dL -0.06 -0.37, 0.26 .73 
Triglycerides, mg/dL 0.05 -0.36, 0.27 .77 
Glucose, mg/dL 0.03 -0.30, 0.34 .87 
C-peptide, ng/mL 0.09 -0.23, 0.39 .59 
Insulin, µIU/mL 0.27 -0.03, 0.53 .12 
Proinsulin / insulin ratio 0.14 -0.18, 0.44 .43 
HOMA-IR 0.22 -0.10, 0.50 .21 
Abbreviations: BMI, body mass index; LDL-cholsterol, low-density lipoprotein cholesterol; 
HDL-cholesterol, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin A1c, 
HOMA-IR, homeostatic model assessment - insulin resistance. 
Correlation analyses were performed with both surgical groups combined and with values after 
cholecystectomy excluded. 
a
11 patients with cholecystectomy at 5 years were excluded from all correlation analyses.  
b
5y minus baseline measurements. 
 
 
 Figure 1. Total bile acid concentrations during 5 years of RYGB and BPD/DS  
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with duodenal 
switch; TBA, total bile acids; GB, gastric bypass; DS, duodenal switch. 
Fasting serum concentrations of total bile acids from each individual measured up to 5 years 
after surgery. Circles represent patients with the gall bladder in situ, while squares represent 
patients with cholecystectomy. Horizontal black lines are observed mean values for the surgical 
group at each time point.   
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